OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - OptiNose reported a quarterly loss of $0.03 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.70, and an improvement from a loss of $1.35 per share a year ago, indicating a 95.71% earnings surprise [1] - The company posted revenues of $22.42 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 5.57% and showing an increase from $19.87 million in the same quarter last year [2] - Over the last four quarters, OptiNose has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - OptiNose shares have increased by approximately 37.3% since the beginning of the year, contrasting with a decline of 1.8% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.74 on revenues of $17.7 million, and for the current fiscal year, it is -$3.13 on revenues of $91.03 million [7] Industry Outlook - The Medical - Drugs industry, to which OptiNose belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]